An international team of researchers has discovered a new and much safer way to treat a type of leukaemia that mainly affects children: T-cell acute lymphoblastic leukemia (T-ALL).
Minderoo Foundation’s $5 million donation to Zero Childhood Cancer will help kids like Jack beat brain cancerMay 15, 2019
Today Minderoo Foundation’s Eliminate Cancer initiative announced a $5 million partnership with Zero to help scale the program in Australia, drive further research into personalised medicine in childhood cancer and help established standardised international protocols.
Children’s Cancer Institute researcher Professor Maria Kavallaris AM – who in January this year was appointed a Member of the Order of Australia for her significant service to medicine and to medical research – today received further recognition for her work, winning the prestigious Lemberg Medal.
Professor Murray Norris AM, Deputy Director of Children’s Cancer Institute and Director of the Centre for Childhood Cancer Research at the University of New South Wales, has won the inaugural Sally Crossing AM Award for an Outstanding Outcome in Cancer Research.
State and Commonwealth Health Ministers, Brad Hazzard and Greg Hunt, announce that a new, world-class Comprehensive Children’s Cancer Centre will be built on the Randwick Hospital Campus, as a new home for Children’s Cancer Institute, and also for an expanded Kid’s Cancer Centre at Sydney Children’s Hospital.
Australian Scientists Discover a Potential Way to Treat and Prevent Cancer in Children with NeuroblastomaFebruary 1, 2019
In new research published this week, a team jointly led by Professors Michelle Haber and Murray Norris has revealed that the polyamine pathway is entirely regulated by the MYCN oncogene
Children’s Cancer Institute is thrilled to announce that Professor Maria Kavallaris – a leading childhood cancer researcher and a pioneer of nanomedicine in Australia – is to be appointed a Member of the Order of Australia. She will be included in the 2019 Australia Day Honours List for her significant service to medicine, and to medical research, in the field of childhood and adult cancers.
For children with the most common childhood cancer, resistance to treatment has remained an enigma – until nowDecember 17, 2018
Research published last week in the prestigious journal, Cancer Cell, by scientists at Children’s Cancer Institute in Sydney, has discovered why one of the most successful classes of drugs used to treat acute lymphoblastic leukaemia (ALL), glucocorticoids, fails to work in 15% of children with the disease.
Tumour cells are known to have high levels of copper. Now researchers at Children’s Cancer Institute in Sydney have found that an antioxidant found in green tea can kill tumour cells by targeting only those with high levels of the metal without harming the healthy cells around them.
Media Release: ‘Zero Childhood Cancer’ Clinical Trial Delivers Promising Results Within Its First 11 MonthsSeptember 2, 2018
The Zero Childhood Cancer program has today released initial results of its national clinical trial, revealing promising outcomes within its first 11 months.
Cancer is diagnosed in more than 950 children and adolescents in Australia every year. Professor Michelle Haber AM, of Children's Cancer Institute and UNSW, was today announced as a finalist for the 2018 Australian Museum Eureka Prize for Leadership in Innovation and Science, sponsored by CSIRO, for her pivotal work in developing the Zero Childhood Cancer program. The program was designed specifically to ensure that those children diagnosed with aggressive cancer have the best possible chance of surviving and doing so with a high quality of life.
Media Release: Prime Minister announces $5 million funding boost for brain cancer personalised trialsJuly 16, 2018
The Zero Childhood Cancer personalised medicine program is the largest single initiative ever undertaken for children with cancer in Australia
This week in the United States, a database of genetic information will be made publicly available of more than 270 patient-derived cancer models, encompassing 25 different childhood cancers. Assisted by funding from the Australian Federal Government Department of Health, Children's Cancer Institute contributed 90 leukaemia models to this global effort.
At the International Nanomedicine Conference in Sydney (25-27 June), Helen Forgham, from Children’s Cancer Institute, is presenting a new technology for targeting the childhood brain cancer medulloblastoma. She’s using star-shaped nanoparticles to deliver gene silencing drugs to tumour cells.
There is a disease that kills children aged between 5 and 10 years old, within one year of diagnosis. New research to be presented at an international conference this week may be about to change that.